Resumen de Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes: Practical lessons from ACCORD and other cardiovascular trials

Matthew C Riddle, Diane M. Karl

• Two other meta-analyses, which added additional randomized studies to the large trials, concluded that available data show limited and inconclusive evidence of risk reduction for CV end points but confirmed a substantial increase of severe hypoglycemia (11,12). The persistent effect of early treatment also suggests that prior poor metabolic control may result in anatomic changes that are not easily reversed. [...]late-stage, high-risk patients of the kind selected for ADVANCE, ACCORD, and VADT may be less likely to benefit from glycémie control after years of hyperglycemia.